Thyroid Eye Disease Market Growth Driven by Targeted Therapies and Pipeline Innovation

Thyroid Eye Disease Market Overview

Thyroid Eye Disease (TED) is an autoimmune inflammatory condition affecting the tissues surrounding the eyes and is frequently associated with thyroid dysfunction, particularly Graves’ disease. Also known as Graves’ orbitopathy or thyroid-associated ophthalmopathy, the condition can cause eyelid retraction, swelling, double vision, proptosis, and potentially severe vision impairment. The thyroid eye disease treatment market is attracting increasing attention as pharmaceutical companies develop targeted therapies to address inflammation and improve visual function. DelveInsight’s analysis covers the seven major markets (7MM), comprising the United States, EU4 countries, the United Kingdom, and Japan, with historical data and forecasts extending through 2034.

Thyroid Eye Disease Market Burden and Epidemiology

TED represents a substantial clinical burden because its symptoms can vary considerably, making early identification challenging, especially among patients with mild or atypical manifestations. According to DelveInsight estimates, approximately 2.386 million people across the 7MM were living with TED in 2022. The patient population is expected to increase during the forecast period as awareness and diagnostic capabilities improve.

The United States accounted for approximately 1.012 million prevalent cases in 2022, representing nearly 42% of the total population across the seven major markets. Germany represented the largest share among the EU4 countries, while Japan contributed approximately 8% of overall cases.

The disease generally progresses through an active inflammatory phase and a subsequent inactive fibrotic phase. The active stage can persist for several months or longer, making the timing of diagnosis and intervention particularly important. Recognizing inflammation early may help healthcare professionals select appropriate treatments and reduce the likelihood of lasting complications.

Thyroid Eye Disease Market Diagnosis and Clinical Management

Diagnosing TED involves a combination of clinical examination, thyroid function testing, antibody assessments, and orbital imaging when indicated. Symptoms may overlap with allergic conjunctivitis and other inflammatory orbital disorders, creating diagnostic challenges. Patients presenting with bilateral proptosis and hyperthyroidism may be easier to diagnose, whereas euthyroid individuals and those experiencing unilateral proptosis can require additional investigations.

Thyroid-stimulating hormone receptor antibodies can provide valuable diagnostic evidence. Computed tomography and magnetic resonance imaging may help evaluate extraocular muscle enlargement, orbital inflammation, and alternative causes of eye protrusion. Timely diagnosis is important because disease activity and severity influence treatment selection.

Clinical management depends on the inflammatory stage, symptom severity, visual function, and patient-specific characteristics. Mild cases may be managed through supportive measures and monitoring, whereas moderate-to-severe disease may require immunomodulatory treatment or specialist intervention.

Thyroid Eye Disease Market Evolution of Treatment Options

Historically, TED management relied on corticosteroids, immunosuppressive medications, orbital radiotherapy, and selected biologic agents. Before the introduction of newer targeted treatments, intravenous corticosteroids and other immunomodulatory approaches were important options for patients with moderate-to-severe active disease.

European Group on Graves’ Orbitopathy guidelines have recommended intravenous methylprednisolone combined with mycophenolate sodium or mycophenolate mofetil in appropriate patients with moderate-to-severe active TED. Patients experiencing severe inflammation, persistent diplopia, or substantial proptosis may require additional therapeutic interventions.

The thyroid eye disease market is gradually shifting toward therapies that target specific biological pathways rather than relying exclusively on conventional immunosuppression. This transition is creating opportunities for innovative medicines that may improve outcomes and address limitations associated with established treatments.

Thyroid Eye Disease Market Impact of TEPEZZA

TEPEZZA (teprotumumab), an insulin-like growth factor-1 receptor-targeting monoclonal antibody, marked an important advancement in TED management following its FDA approval in 2020. It was the first FDA-approved treatment specifically developed for the condition and has demonstrated improvements in proptosis, diplopia, disease activity, and quality of life in clinical studies.

The introduction of this targeted therapy has influenced the exophthalmos treatment market, where reducing eye protrusion is a major therapeutic objective. Its clinical benefits have expanded treatment possibilities for eligible patients who previously depended on corticosteroids, other immunosuppressants, or surgical interventions.

Nevertheless, treatment decisions must account for potential adverse effects, contraindications, affordability, and patient suitability. These considerations continue to influence access and adoption across different healthcare systems.

Thyroid Eye Disease Market Growth Drivers

Several factors are expected to support market expansion through the forecast period. Increasing disease awareness, improvements in diagnostic techniques, and greater recognition of mild or previously undiagnosed cases could expand the population eligible for treatment. The introduction of targeted biologics has also increased interest in TED among clinicians, patients, and pharmaceutical developers.

The broader US thyroid disorder market provides an important clinical backdrop because TED is associated with thyroid autoimmunity and frequently occurs in patients with Graves’ disease. However, its distinctive ocular manifestations require specialized diagnosis and management, establishing a separate therapeutic opportunity.

Additional growth opportunities may emerge from improved referral pathways, earlier intervention, greater access to specialist care, and treatment strategies designed to prevent long-term visual impairment.

Thyroid Eye Disease Market Emerging Pipeline Therapies

The development pipeline is expected to influence competition and treatment choices significantly. Batoclimab, VRDN-001, and COSENTYX (secukinumab) have been highlighted in discussions of emerging or investigational approaches to TED. Their mechanisms, clinical evidence, and development status differ, making continued evaluation necessary to determine their potential roles in clinical practice.